Researchers conducted a post hoc analysis of the SURMOUNT-1 trial to assess the effect of tirzepatide on kidney function in prediabetes with obesity or overweight.

Tatiana De La Rosa is leaving carb-cutting behind (and scaling back her love of tequila) on compounded tirzepatide.

The FDA has updated the labeling for Kisunla™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer disease.

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

Novo Nordisk NVO announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking ...

Top-Line Data Expected in the Fourth Quarter of 2025 CAMBRIDGE, Mass., July 9, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology ...

A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with ...

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.

Introduction For over more than a decade, low-dose amitriptyline and mirtazapine are prescribed off-label for insomnia. However, placebo-controlled evidence on these antidepressants for insomnia is ...

Joie Armstrong asked her doctor about taking a GLP-1 medication to help her lose weight six times before she got a prescription, and then was denied coverage by her insurance company. Adrian, a ...

ADR was reported in each dosage of tirzepatide, with the most occurring at 2.5–5 mg (16 cases), and primarily occurred within 1–6 months of initiation. Regarding rechallenge, 15 patients discontinued ...

Packages valued at less than $800 that enter the U.S. under the de minimis rule are not included in the data. Bar chart showing unregistered shipments of tirzepatide and semaglutide from China.